Concert Pharmaceuticals' once-a-day candidate begins trials; Study supportive of Genentech's injectable eye drug;

> Concert Pharmaceuticals announced it has begun Phase I study of its candidate for cystic fibrosis, which it hopes will enable once-a-day dosing. More

> A study in the Journal of the American Medical Association found that injection of Genentech's eye drug Lucentis performed noninferiorly to a laser-based procedure treating diabetic retinopathy. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.